Therapeutic Strategy for Efficient Reduction of Serum Uric Acid Levels with Allopurinol versus Benzbromarone in Hyperuricemic Patients with Essential Hypertension-A Randomized Crossover Study (TERAO study)

Therapeutic Strategy for Efficient Reduction of Serum Uric Acid Levels with Allopurinol versus Benzbromarone in Hyperuricemic Patients with Essential Hypertension-A Randomized Crossover Study (TERAO study) - TERAO study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023905

Enrollment

Registered

2016-09-02

Start date

2013-06-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hyperuricemia

Interventions

We randomized 7 consecutive patients with microalbuminuria having hypertension (&gt

140/90 mm Hg or taking anti-hypertensive medications) and hyperuricemia (serum uric acid levels &gt

7 mg/dL) to receive either benzbromarone 25 mg once daily for the first four weeks of the study. We randomized 7 consecutive patients with microalbuminuria having hypertension (&gt

7 mg/dL) to receive allopurinol 200 mg twice daily for the first four weeks of the study.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients having hypertension (>140/90 mm Hg or taking anti-hypertensive medications) and hyperuricemia (serum uric acid levels >7 mg/dL).

Exclusion criteria

Exclusion criteria: patients in whom informed consent could not be received.

Design outcomes

Primary

Measure	Time frame
the change of serum and urine urate and proteinuria	—

Countries

Japan

Contacts

Public ContactSunao Kojima

Kumamoto University Cardiovascular medicine

kojimas@kumamoto-u.ac.jp096-373-5175

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026